Various methods have been proposed to solve this challenge: extension of the duration of PPI clarithromycin-based triple therapies; sequential therapy; quadruple therapies; and levofloxacin as a substitute to clarithromycin in PPI triple therapies.
Zhejiang Jingxin Pharmaceutical Co., Ltd.
Top 100 Pharmaceutical Enterprises and the Listed Company SZ.002020